

Patent
Our Docket: 1011CON1.2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Couto et al.)	Art Unit: 1635
Serial No.: 10/632,645)	Examiner: Brian A. Whiteman
Filed: August 1, 2003)	
For: Adeno-associated vector)	
compositions for expression of)	
Factor VIII)	

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING ELECTRONICALLY FILED WITH THE UNITED STATES
PATENT AND TRADEMARK OFFICE.

September 21, 2007

Date

/Jennifer D. Tousignant/

Signature of person filing correspondence

Terminal Disclaimer under 37 C.F.R. § 1.321(b)

Sir:

1. I, Jennifer D. Tousignant, state that I am the agent of record in the above referenced patent application. I am a representative authorized to sign this document on behalf of Genzyme Corporation, the assignee for this invention.

2. Assignee Genzyme Corporation is a corporation having a principal place of business at 500 Kendall Street, Cambridge, MA 02142.

3. Genzyme Corporation is the owner of the entire right, title, and interest in the invention disclosed and claimed in United States Patent Application Serial No. 10/632,645, filed August 1, 2003. Genzyme Corporation is also the owner of the entire right, title, and interest in the inventions disclosed and claimed in United States Patent Serial Nos. 6,200,560 and 6,221,349.

4. The Assignee hereby disclaims the terminal part of any patent granted on United States Application Patent Serial No. 10/632,645 that would extend beyond the expiration date of United States Patent Serial Nos. 6,200,560 and 6,221,349 and agrees that any patent granted on the herein United States Patent Application Serial No. 10/632,645 will be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to United States Patent Serial Nos.

6,200,560 and 6,221,349; this agreement to run with any patent granted on United States Patent Application Serial No. 10/632,645 and to be binding upon the grantees, their successors or assigns.

5. In making this disclaimer, Assignee does not disclaim the terminal part of any patent granted on United States Patent Application Serial No. 10/632,645 that would extend to the expiration date to the full statutory term as defined in 35 U.S.C. §§ 154-156 and 173 of United States Patent Serial Nos. 6,200,560 and 6,221,349, as presently shortened by any terminal disclaimer in the event that it later (a) expires for failure to pay a maintenance fee, (b) is held unenforceable, (c) is found invalid by a court of competent jurisdiction, (d) is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321, (e) has all claims canceled by a reexamination certificate, (f) is reissued, or (g) is, in any manner, terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

6. The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17, and 1.21, which may be required by this paper, or to credit any overpayment to Deposit Account No. 07-1074.

Executed at: Framingham, MA 01701

By: /Jennifer D. Tousignant/
Jennifer D. Tousignant

Title: Agent of Record; Registration No. 54,498

Date: September 21, 2007